Modulating lgG effector function by FC engineering and glycoengineering

By Andy Racher of Lonza Biologics

Antibodies are the fastest growing group of biotherapeutics. In early 2020 more than 100 antibody-based molecules, including biosimilars, had been approved globally. Oncology and inflammatory disorders remain the major therapeutic areas for antibody-based molecules but there is a growing interest in using mAbs for treating infectious disease. During the last 10 years antibody engineering focussed on development of “fit-for-purpose” antibodies with modulated effector functions such as increased or muted antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC), and to increase half-life. This paper summarises approaches for modulating antibody effector functions and pharmacokinetics, and provides examples of antibodies in clinical studies employing such approaches.



You can follow the latest on early phase clinical development with the Bench to Clinic Blog.

Lorem ipsum dolor sit amet